Patrick Mc Carville, MD
Family Medicine · Valley, NENPI 1891803698
Payments from drug & device makers
Across 83 payments — averaging $15.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$258
- Boehringer Ingelheim$199
- Novo Nordisk$148
- Amgen$100
- Novartis$78
- Johnson & Johnson$70
- plus $402 from 14 others
What the payments were for
- Food & beverage$1,250100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 13 | $258 |
| Boehringer Ingelheim | 16 | $199 |
| Novo Nordisk | 12 | $148 |
| Amgen | 6 | $100 |
| Novartis | 6 | $78 |
| Johnson & Johnson | 4 | $70 |
| Bristol Myers Squibb | 3 | $52 |
| Kowa Pharmaceuticals America, Inc. | 4 | $51 |
| Pfizer | 3 | $46 |
| Mylan Specialty L.p. | 2 | $39 |
| Lilly USA, LLC | 3 | $37 |
| AbbVie(2 entities) | 2 | $33 |
| Ironshore Pharmaceuticals Inc. | 2 | $25 |
| Corcept Therapeutics | 1 | $22 |
| Astellas Pharma US Inc | 1 | $20 |
| Genentech USA, Inc. | 1 | $17 |
| Merck | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Exact Sciences | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,256 in reported general payments places this provider in the 65th percentile of 981 family medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 255 | $174,622 |
| JardianceEmpagliflozin | 116 | $133,941 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 71 | $83,545 |
| CopaxoneGlatiramer Acetate | 13 | $74,599 |
| OzempicSemaglutide | 50 | $62,867 |
| XareltoRivaroxaban | 53 | $52,869 |
| GlyxambiEmpagliflozin/Linagliptin | 28 | $45,614 |
| MyrbetriqMirabegron | 59 | $38,737 |
| TrulicityDulaglutide | 24 | $37,185 |
| FarxigaDapagliflozin Propanediol | 22 | $31,148 |
| JanuviaSitagliptin Phosphate | 17 | $27,551 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 34 | $24,943 |
| JanumetSitagliptin Phos/Metformin Hcl | 12 | $19,717 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 12 | $15,837 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 44 | $15,181 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Glyxambi, Trijardy Xr | $199 | $195,392156 claims |
| PfizerEliquis | $46 | $174,622255 claims |
| Novo NordiskOzempic | $148 | $62,86750 claims |
| Johnson & JohnsonXarelto | $70 | $52,86953 claims |
| MerckJanuvia, Janumet | $16 | $47,26829 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort | $258 | $41,45163 claims |
| Astellas Pharma US IncMyrbetriq | $20 | $38,73759 claims |
| Lilly USA, LLCTrulicity | $37 | $37,18524 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 981 family medicine providers in Nebraska.
Other family medicine in Valley
- Brandon EssinkCreighton$92.8M
- Adam BroszGrand Island$60M
- David EnszSouth Sioux City$33.3M
- Allen HuntLincoln$17.2M
- Thomas WolfFremont$8.2M
- William FitzgibbonsElkhorn$7M
- Kenneth BladOmaha$1.6M
- Lorrie McGillPapillion$1.5M
- Ralph HaukeOmaha$657K
- Darin GregoryOmaha$423K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.